Therapy of mouse lymphoma with monoclonal antibodies to glycolipid: selection of low antigenic variants in vivo.
Growth of mouse lymphoma L5178Y, which contains large quantitites of the gangliotriosylceramide (GgOs3Cer), in DBA/2 mice was suppressed by passive immunization with monoclonal immunoglobulin G3 antibodies to GgOS3Cer, but not by immunoglobulin M antibodies with or without added complement. Most groups of mice treated with monoclonal immunoglobulin G3 antibodies did not develop tumors, but the tumor that appeared in a treated animal had a much lower amount of the GgOS3Cer than the cells used for inoculation. Thus, passive immunization either prevented growth of the lymphoma or caused selection of a variant with a lower quantity of the antigen GgOS3Cer.
D000818:Animals; D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D002999:Clone Cells / Q000276:immunology; D006017:Glycolipids / Q000276:immunology*; D006822:Hybrid Cells / Q000276:immunology; D007116:Immunization, Passive; D007074:Immunoglobulin G / Q000008:administration & dosage; D007075:Immunoglobulin M / Q000008:administration & dosage; D007167:Immunotherapy; D008223:Lymphoma / Q000276:immunology / Q000628:therapy*; D051379:Mice; D009374:Neoplasms, Experimental / Q000628:therapy
D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D006017:Glycolipids; D007074:Immunoglobulin G; D007075:Immunoglobulin M